PURR-04

PURR-04 is an experimental veterinary drug candidate under development by The Cat Health Company, a biotechnology firm specializing in feline geroscience. The drug is part of the company's 'PURR' pipeline, which focuses on longevity medicines designed to address the primary age-related diseases in senior cats. Specifically, PURR-04 is being developed to target sarcopenia (muscle wasting), chronic kidney disease (CKD), and neurodegeneration (feline cognitive dysfunction). The therapeutic objective of PURR-04 is to intervene in the biological pathways of aging to extend the healthy lifespan and improve the quality of life for geriatric feline populations. While the specific molecular target and modality are not publicly disclosed, the candidate is positioned within a broader strategy of applying longevity science to veterinary medicine.